» Articles » PMID: 10223925

Streptococcus Pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones

Overview
Specialty Pharmacology
Date 1999 May 1
PMID 10223925
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Streptococcus pneumoniae gyrA and gyrB genes specifying the DNA gyrase subunits have been cloned into pET plasmid vectors under the control of an inducible T7 promoter and have been separately expressed in Escherichia coli. Soluble 97-kDa GyrA and 72-kDa GyrB proteins bearing polyhistidine tags at their respective C-terminal and N-terminal ends were purified to apparent homogeneity by one-step nickel chelate column chromatography and were free of host E. coli topoisomerase activity. Equimolar amounts of the gyrase subunits reconstituted ATP-dependent DNA supercoiling with comparable activity to gyrase of E. coli and Staphylococcus aureus. In parallel, S. pneumoniae topoisomerase IV ParC and ParE subunits were similarly expressed in E. coli, purified to near homogeneity as 93- and 73-kDa proteins, and shown to generate efficient ATP-dependent DNA relaxation and DNA decatenation activities. Using the purified enzymes, we examined the inhibitory effects of three paradigm fluoroquinolones-ciprofloxacin, sparfloxacin, and clinafloxacin-which previous genetic studies with S. pneumoniae suggested act preferentially through topoisomerase IV, through gyrase, and through both enzymes, respectively. Surprisingly, all three quinolones were more active in inhibiting purified topoisomerase IV than gyrase, with clinafloxacin showing the greatest inhibitory potency. Moreover, the tested agents were at least 25-fold more effective in stabilizing a cleavable complex (the relevant cytotoxic lesion) with topoisomerase IV than with gyrase, with clinafloxacin some 10- to 32-fold more potent against either enzyme, in line with its superior activity against S. pneumoniae. The uniform target preference of the three fluoroquinolones for topoisomerase IV in vitro is in apparent contrast to the genetic data. We interpret these results in terms of a model for bacterial killing by quinolones in which cellular factors can modulate the effects of target affinity to determine the cytotoxic pathway.

Citing Articles

Interactions between Gepotidacin and Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting.

Oviatt A, Gibson E, Huang J, Mattern K, Neuman K, Chan P ACS Infect Dis. 2024; 10(4):1137-1151.

PMID: 38606465 PMC: 11015057. DOI: 10.1021/acsinfecdis.3c00346.


Ribonucleotide reductase, a novel drug target for gonorrhea.

Narasimhan J, Letinski S, Jung S, Gerasyuto A, Wang J, Arnold M Elife. 2022; 11.

PMID: 35137690 PMC: 8865847. DOI: 10.7554/eLife.67447.


Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase.

Laponogov I, Pan X, Veselkov D, Skamrova G, Umrekar T, Fisher L Nat Commun. 2018; 9(1):2579.

PMID: 29968711 PMC: 6030046. DOI: 10.1038/s41467-018-05005-x.


Activities of gyrase and topoisomerase IV on positively supercoiled DNA.

Ashley R, Dittmore A, McPherson S, Turnbough Jr C, Neuman K, Osheroff N Nucleic Acids Res. 2017; 45(16):9611-9624.

PMID: 28934496 PMC: 5766186. DOI: 10.1093/nar/gkx649.


Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance.

Ashley R, Lindsey Jr R, McPherson S, Turnbough Jr C, Kerns R, Osheroff N Biochemistry. 2017; 56(32):4191-4200.

PMID: 28708938 PMC: 5560241. DOI: 10.1021/acs.biochem.7b00203.


References
1.
Khodursky A, Cozzarelli N . The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem. 1998; 273(42):27668-77. DOI: 10.1074/jbc.273.42.27668. View

2.
Zechiedrich E, Cozzarelli N . Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev. 1995; 9(22):2859-69. DOI: 10.1101/gad.9.22.2859. View

3.
Mizuuchi K, Fisher L, ODea M, Gellert M . DNA gyrase action involves the introduction of transient double-strand breaks into DNA. Proc Natl Acad Sci U S A. 1980; 77(4):1847-51. PMC: 348605. DOI: 10.1073/pnas.77.4.1847. View

4.
Pan X, Fisher L . Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996; 178(14):4060-9. PMC: 178161. DOI: 10.1128/jb.178.14.4060-4069.1996. View

5.
Munoz R, de la Campa A . ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996; 40(10):2252-7. PMC: 163513. DOI: 10.1128/AAC.40.10.2252. View